(CBLL) CeriBell - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 712m USD | Total Return: 8.8% in 12m
Avg Turnover: 5.77M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -35.0 is critical
Altman Z'' -7.84 < 1.0 - financial distress zone
Tailwinds
Idiosyncratic Leader
CeriBell, Inc. (CBLL) is a medical technology firm specializing in point-of-care electroencephalogram (EEG) systems for acute care environments. The companys core offering consists of a proprietary platform integrating hardware, such as rechargeable recorders and disposable headbands, with a cloud-based portal for remote data access. By utilizing an AI-powered algorithm named Clarity, the system provides automated seizure detection to assist clinicians in rapid diagnosis.
Operating within the Health Care Equipment sector, CeriBell utilizes a razor-and-blade business model where the initial sale of EEG recorders is supplemented by recurring revenue from single-use disposable components. This approach addresses a critical bottleneck in neurology, as traditional EEG monitoring often requires specialized technicians and lengthy setup times that are unavailable in emergency settings. For those seeking deeper insights into the companys financial health, ValueRay offers additional fundamental analysis.
Headquartered in Sunnyvale, California, the company rebranded from Brain Stethoscope, Inc. in 2015. Its technological focus remains on decentralizing neurological monitoring, shifting high-complexity diagnostics from specialized labs directly to the patients bedside in intensive care units and emergency departments.
- Hospital adoption of point-of-care EEG systems drives core hardware and software revenue
- Recurring sales of disposable headbands scale alongside increasing patient monitoring volume
- FDA clearance of AI-powered seizure detection algorithms enhances competitive market positioning
- Expansion of clinical evidence supporting EEG use in ICUs accelerates hospital procurement
- Reimbursement policy changes for neurocritical care monitoring impact long-term profitability margins
| Net Income: -60.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -9.87 > 1.0 |
| NWC/Revenue: 158.3% < 20% (prev 272.4%; Δ -114.1% < -1%) |
| CFO/TA -0.27 > 3% & CFO -48.9m > Net Income -60.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.7m) vs 12m ago 4.97% < -2% |
| Gross Margin: 87.72% > 18% (prev 0.87%; Δ 8.68k% > 0.5%) |
| Asset Turnover: 48.56% > 50% (prev 33.30%; Δ 15.26% > 0%) |
| Interest Coverage Ratio: -35.05 > 6 (EBITDA TTM -63.7m / Interest Expense TTM 1.85m) |
| A: 0.85 (Total Current Assets 166.7m - Total Current Liabilities 16.2m) / Total Assets 178.1m |
| B: -1.35 (Retained Earnings -240.1m / Total Assets 178.1m) |
| C: -0.33 (EBIT TTM -64.9m / Avg Total Assets 195.8m) |
| D: -6.44 (Book Value of Equity -240.0m / Total Liabilities 37.3m) |
| Altman-Z'' = -7.84 = D |
| DSRI: 1.04 (Receivables 15.7m/11.3m, Revenue 95.1m/71.1m) |
| GMI: 0.99 (GM 87.72% / 87.24%) |
| AQI: 2.21 (AQ_t 0.04 / AQ_t-1 0.02) |
| SGI: 1.34 (Revenue 95.1m / 71.1m) |
| TATA: -0.06 (NI -60.4m - CFO -48.9m) / TA 178.1m) |
| Beneish M = -2.11 (Cap -4..+1) = BB |
As of May 27, 2026, the stock is trading at USD 18.80 with a total of 179,522 shares traded.
Over the past week, the price has changed by +13.39%,
over one month by -11.07%,
over three months by -3.04% and
over the past year by +8.80%.
CeriBell has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy CBLL.
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.9 | 42.9% |
P/S = 7.4915
P/B = 5.0509
Revenue TTM = 95.1m USD
EBIT TTM = -64.9m USD
EBITDA TTM = -63.7m USD
Long Term Debt = 19.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.14m USD (from shortTermDebt, last quarter)
Debt = 24.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.20m
Net Debt = -116.9m USD (calculated: Debt 24.3m - CCE 141.2m)
Enterprise Value = 595.3m USD (712.2m + Debt 24.3m - CCE 141.2m)
Interest Coverage Ratio = -35.05 (Ebit TTM -64.9m / Interest Expense TTM 1.85m)
EV/FCF = -12.00x (Enterprise Value 595.3m / FCF TTM -49.6m)
FCF Yield = -8.33% (FCF TTM -49.6m / Enterprise Value 595.3m)
FCF Margin = -52.17% (FCF TTM -49.6m / Revenue TTM 95.1m)
Net Margin = -63.51% (Net Income TTM -60.4m / Revenue TTM 95.1m)
Gross Margin = 87.72% ((Revenue TTM 95.1m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Gross Margin QoQ = 87.27% (prev 87.33%)
Tobins Q-Ratio = 3.34 (Enterprise Value 595.3m / Total Assets 178.1m)
Interest Expense / Debt = 7.62% (Interest Expense 1.85m / Debt 24.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -51.3m (EBIT -64.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.30 (Total Current Assets 166.7m / Total Current Liabilities 16.2m)
Debt / Equity = 0.17 (Debt 24.3m / totalStockholderEquity, last quarter 140.8m)
Debt / EBITDA = 1.83 (negative EBITDA) (Net Debt -116.9m / EBITDA -63.7m)
Debt / FCF = 2.36 (negative FCF - burning cash) (Net Debt -116.9m / FCF TTM -49.6m)
Total Stockholder Equity = 158.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.84% (Net Income -60.4m / Total Assets 178.1m)
RoE = -15.16% (Net Income TTM -60.4m / Total Stockholder Equity 398.2m)
RoCE = -15.53% (EBIT -64.9m / Capital Employed (Equity 398.2m + L.T.Debt 19.9m))
RoIC = -38.31% (negative operating profit) (NOPAT -51.3m / Invested Capital 133.9m)
WACC = 9.97% (E(712.2m)/V(736.5m) * Re(10.11%) + D(24.3m)/V(736.5m) * Rd(7.62%) * (1-Tc(0.21)))
Discount Rate = 10.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.40 | Cagr: 23.74%
[DCF] Fair Price = unknown (Cash Flow -49.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 99.86 | Revenue CAGR: 40.33% | SUE: 0.63 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.46 | Chg30d=-17.57% | Revisions=-43% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=-5.56% | Revisions=-14% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.68 | Chg30d=-15.51% | Revisions=-43% | GrowthEPS=-15.2% | GrowthRev=+28.0%
EPS next Year (2027-12-31): EPS=-1.10 | Chg30d=-9.22% | Revisions=-25% | GrowthEPS=+34.7% | GrowthRev=+28.0%
[Analyst] Revisions Ratio: -43%